International Journal of Academic Health and Medical Research (IJAHMR)   Year: 2023 | Volume: 7 | Issue: 3 | Page No.: 1-5 Endometrial Thickness in Tamoxifen-Treated Patients (About 64 Cases) Download PDF Sanae STIMOU, Hafsa TAHERI, Hanane SAADI, Ahmed MIMOUNI Abstract: The objective of our work is to determine the impact of tamoxifen on the genesis of endometrial lesions, to discuss the place of screening for endometrial pathologies under tamoxifen, to compare our results with the data of the literature. This is a retrospective analytical study conducted in the department of Gynecology-Obstetrics of CHU Mohammed VI of Oujda in Morocco, over a period of 5 years. Sixty-four cases of endometrial lesions under tamoxifen were recorded. In our series, 64 cases of endometrial lesions under tamoxifen were recorded. All patients received tamoxifen at a daily dose of 20 mg. Postmenopausal metrorrhagia and the discovery of endometrial thickening by surveillance ultrasound were the main circumstances of discovery. 53.1% of cases were discovered during ultrasound surveillance of asymptomatic patients and 46.9% of cases by metrorrhagia. Hysteroscopy with biopsies was used to diagnose the various endometrial lesions under tamoxifen. The risk of endometrial cancer increases significantly with the duration and total cumulative dose of tamoxifen. The majority of endometrial abnormalities found (89%) were benign. 6 cases of atypical hyperplasia (9.4%) and one case of endometrial cancer were diagnosed. These results call into question the place of endometrial cancer screening under tamoxifen. Screening for endometrial cancer on tamoxifen is not systematic in all patients. Surveillance remains justified in women at high risk of developing endometrial carcinoma.